BCR-ABL1 Quantitative p210p190p230 Test
Components: EDTA Vacutainer (4ml)
Price: 1800.0 AED
Sample Condition: Bone marrow / Peripheral blood (Transport immediately)
Report Delivery: 3-4 days
Method: Real Time PCR
Test Type: Genetics
Doctor: General Physician
Test Department:
Pre Test Information
BCR-ABL1 Quantitative (p210,p190,p230) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
BCR-ABL1 quantitative testing is a molecular diagnostic test used to monitor the response to treatment and detect minimal residual disease in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL1 is a fusion gene formed by the translocation of chromosomes 9 and 22, resulting in the production of a chimeric protein with constitutive tyrosine kinase activity.
The BCR-ABL1 quantitative test measures the level of BCR-ABL1 transcripts in the patient’s blood or bone marrow sample. It can detect different variants of the BCR-ABL1 fusion gene, including p210, p190, and p230. These variants are named after their molecular weight and are associated with different subtypes of CML and Ph+ ALL.
The test is typically performed using a technique called real-time quantitative polymerase chain reaction (qPCR). It involves extracting RNA from the patient’s sample and converting it into complementary DNA (cDNA). The cDNA is then amplified using specific primers and probes that target the BCR-ABL1 fusion gene. The level of BCR-ABL1 transcripts is quantified by comparing it to a reference gene, and the results are reported as a ratio or percentage.
Monitoring the BCR-ABL1 transcript levels over time allows healthcare providers to assess the response to treatment and make adjustments if necessary. A significant reduction or elimination of BCR-ABL1 transcripts indicates a good response to therapy, while an increase may suggest disease progression or treatment resistance.
The BCR-ABL1 quantitative test is a critical tool in the management of CML and Ph+ ALL. It helps guide treatment decisions, such as the initiation of therapy, dose adjustments, and the consideration of alternative treatment options.
| Test Name | BCR-ABL1 Quantitative p210p190p230 Test |
|---|---|
| Components | EDTA Vacutainer (4ml) |
| Price | 1800.0 AED |
| Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
| Report Delivery | 3-4 days |
| Method | Real Time PCR |
| Test type | Genetics |
| Doctor | General Physician |
| Test Department: | |
| Pre Test Information | BCR-ABL1 Quantitative (p210,p190,p230) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
BCR-ABL1 quantitative testing is a molecular diagnostic test used to monitor the response to treatment and detect minimal residual disease in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL1 is a fusion gene formed by the translocation of chromosomes 9 and 22, resulting in the production of a chimeric protein with constitutive tyrosine kinase activity. The BCR-ABL1 quantitative test measures the level of BCR-ABL1 transcripts in the patient’s blood or bone marrow sample. It can detect different variants of the BCR-ABL1 fusion gene, including p210, p190, and p230. These variants are named after their molecular weight and are associated with different subtypes of CML and Ph+ ALL. The test is typically performed using a technique called real-time quantitative polymerase chain reaction (qPCR). It involves extracting RNA from the patient’s sample and converting it into complementary DNA (cDNA). The cDNA is then amplified using specific primers and probes that target the BCR-ABL1 fusion gene. The level of BCR-ABL1 transcripts is quantified by comparing it to a reference gene, and the results are reported as a ratio or percentage. Monitoring the BCR-ABL1 transcript levels over time allows healthcare providers to assess the response to treatment and make adjustments if necessary. A significant reduction or elimination of BCR-ABL1 transcripts indicates a good response to therapy, while an increase may suggest disease progression or treatment resistance. The BCR-ABL1 quantitative test is a critical tool in the management of CML and Ph+ ALL. It helps guide treatment decisions, such as the initiation of therapy, dose adjustments, and the consideration of alternative treatment options. |
